Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
25 hedge funds and large institutions have $9.3M invested in Argos Therapeutics, Inc. in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 5 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
4% less funds holding
Funds holding: 26 → 25 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
58% less capital invested
Capital invested by funds: $22M → $9.3M (-$12.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PSI
Pinnacle Summer Investments
Fairfax,
Virginia
|
+$264K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$246K |
| 3 |
Renaissance Technologies
New York
|
+$151K |
| 4 |
SIM
Spark Investment Management
New York
|
+$145K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$75.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$3.49M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$154K |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$95.2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$23K |
| 5 |
SIP
Stoneridge Investment Partners
Radnor,
Pennsylvania
|
-$14.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
26
Credit Suisse
Zurich,
Switzerland
| – | -$154K | -1,598 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$23K | -240 | Closed |
|
28
UBS Group
Zurich,
Switzerland
| – | -$13K | -137 | Closed |
|
29
Citigroup
New York
| – | -$1K | -8 | Closed |
|
30
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$1.01K | +12 | New |
|
ARGS Hedge Fund Activity: Q4 2015 in Review
25 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q4 2015, worth a combined $9.3M — down 58% from $22M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ARGS and 4 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 7 added.
The largest buyer was Pinnacle Summer Investments, adding an estimated $264K. The largest seller was AWM Investment Company, exiting entirely with an estimated $3.49M sold.
- 25 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q4 2015, down from 26 in Q3 2015.
- Funds reported $9.3M of Argos Therapeutics, Inc. stock for Q4 2015, down 58% quarter-over-quarter.
- 4 funds opened new Argos Therapeutics, Inc. positions in Q4 2015 and 5 closed out, a net change of -1 holder.
- The largest Argos Therapeutics, Inc. buyer in Q4 2015 was Pinnacle Summer Investments, an estimated $264K added.
- The largest Argos Therapeutics, Inc. seller in Q4 2015 was AWM Investment Company, an estimated $3.49M sold.
Based on aggregated 13F filings for Q4 2015.